An­oth­er an­tibi­ot­ic mak­er bites the dust, as Tetraphase is swal­lowed for cheap

Some four years af­ter it re­port­ed its first batch of piv­otal tri­al da­ta, Tetraphase fi­nal­ly se­cured FDA ap­proval for its lead an­tibi­ot­ic, er­ava­cy­cline, for com­pli­cat­ed in­tra-ab­dom­i­nal in­fec­tions in 2018. But like many of its peers, mere­ly se­cur­ing ap­proval was on­ly the first hur­dle.

The big­ger ob­sta­cle was reap­ing the re­turns in a “bro­ken” mar­ket for an­tibi­otics. On Mon­day, the Mass­a­chu­setts-based com­pa­ny said it was be­ing ac­quired by Acel­Rx in an all-stock deal val­ued at a pal­try $14.4 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER